Inventor · disambiguated record
Edward Norbert Van Den Brink
Also filed as: VAN DEN BRINK EDWARD · VAN DEN BRINK EDWARD N · VAN DEN BRINK EDWARD NORBERT
55 granted patents·32 pending applications·566 citations·filing 1999–2025
99Inventor score
Files withGENMAB AS43H LUNDBECK AS20GENMAB HOLDING B V7CRUCELL HOLLAND BV6VAN DEN BRINK EDWARD NORBERT4
Top patents by PatentIndex Score
87 records- 0198US11542323B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Jan 3, 2023·6 cites·24 claims
- 0298US11524995B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Dec 13, 2022·6 cites·20 claims
- 0398US11485796B2Inert formatGENMAB AS·Filed 2020·Granted Nov 1, 2022·6 cites·20 claims
- 0497US11421024B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2020·Granted Aug 23, 2022·6 cites·23 claims
- 0597US10800836B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2016·Granted Oct 13, 2020·10 cites·10 claims
- 0697US10647764B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 0797US10647763B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 12, 2020·9 cites·14 claims
- 0897US10640554B2Agents, uses and methods for the treatment of synucleinopathyH LUNDBECK AS·Filed 2019·Granted May 5, 2020·9 cites·14 claims
- 0997US8691223B2Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereofVAN DEN BRINK EDWARD NORBERT·Filed 2011·Granted Apr 8, 2014·63 cites·12 claims
- 1096US10590206B2Inert formatGENMAB AS·Filed 2014·Granted Mar 17, 2020·29 cites·20 claims
- 1196US10364285B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 30, 2019·13 cites·9 claims
- 1296US10358484B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 1396US10358483B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·13 cites·9 claims
- 1496US8192927B2Human bind molecules capable of neutralizing influenza virus h5n1 and uses thereofVAN DEN BRINK EDWARD NORBERT·Filed 2007·Granted Jun 5, 2012·53 cites·11 claims
- 1595US11396553B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2021·Granted Jul 26, 2022·8 cites·23 claims
- 1695US10358482B2Antibodies for the treatment of synucleinopathyH LUNDBECK AS·Filed 2017·Granted Jul 23, 2019·11 cites·9 claims
- 1795US7696330B2Binding molecules against SARS-coronavirus and uses thereofCRUCELL HOLLAND BV·Filed 2006·Granted Apr 13, 2010·68 cites·11 claims
- 1894US11512137B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Nov 29, 2022·10 cites·10 claims
- 1994US11034772B2Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereofGENMAB HOLDING B V·Filed 2020·Granted Jun 15, 2021·7 cites·20 claims
- 2094US10407501B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2015·Granted Sep 10, 2019·15 cites·19 claims
- 2193US10544220B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2016·Granted Jan 28, 2020·18 cites·12 claims
- 2293US8106170B2Compositions against SARS-coronavirus and uses thereofTER MEULEN JAN HENRIK·Filed 2005·Granted Jan 31, 2012·48 cites·11 claims
- 2392US11613575B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2019·Granted Mar 28, 2023·4 cites·18 claims
- 2492US10479835B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2016·Granted Nov 19, 2019·4 cites·16 claims
- 2592US10428147B2Anti-sortilin antibodies, uses and methods for treatmentH LUNDBECK AS·Filed 2016·Granted Oct 1, 2019·4 cites·7 claims
- 2692US9657107B2Monoclonal antibodies against c-MetGENMAB AS·Filed 2015·Granted May 23, 2017·9 cites·25 claims
- 2791US11008399B2AntibodiesGENMAB AS·Filed 2020·Granted May 18, 2021·2 cites·22 claims
- 2891US10465006B2Humanized or chimeric CD3 antibodiesGENMAB·Filed 2014·Granted Nov 5, 2019·18 cites·19 claims
- 2990US10889650B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2019·Granted Jan 12, 2021·2 cites·19 claims
- 3090US10201607B2Antibodies binding AXLGENMAB AS·Filed 2018·Granted Feb 12, 2019·7 cites·28 claims
- 3190US9862769B2Monoclonal antibodies against HER2DE GOEIJ BART·Filed 2011·Granted Jan 9, 2018·16 cites·42 claims
- 3290US9714294B2Monoclonal antibodies against HER2 epitopeDE GOEIJ BART·Filed 2011·Granted Jul 25, 2017·17 cites·43 claims
- 3389US10765743B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Sep 8, 2020·3 cites·46 claims
- 3488US11548950B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2020·Granted Jan 10, 2023·1 cites·19 claims
- 3588US11130819B2AntibodiesGENMAB AS·Filed 2021·Granted Sep 28, 2021·1 cites·30 claims
- 3688US9068011B2Monoclonal antibodies against c-MetNEIJSSEN JOOST J·Filed 2011·Granted Jun 30, 2015·12 cites·24 claims
- 3788US7888102B2Cell line for producing coronavirusesCRUCELL HOLLAND BV·Filed 2006·Granted Feb 15, 2011·9 cites·12 claims
- 3887US10500276B2Antibodies binding AXLGENMAB AS·Filed 2019·Granted Dec 10, 2019·4 cites·35 claims
- 3986US11459395B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2021·Granted Oct 4, 2022·1 cites·19 claims
- 4086US10512688B2Antibodies binding AXLGENMAB AS·Filed 2015·Granted Dec 24, 2019·4 cites·8 claims
- 4185US11046771B2Monoclonal antibodies against HER2GENMAB AS·Filed 2017·Granted Jun 29, 2021·2 cites·23 claims
- 4285US8802089B2Monoclonal antibodies against CD32BVAN DEN BRINK EDWARD NORBERT·Filed 2008·Granted Aug 12, 2014·7 cites·36 claims
- 4385US2024392032A1AntibodiesGENMAB AS·Filed 2024·Application pending·0 cites
- 4485US2023312693A1Agents, Uses and Methods for the Treatment of SynucleinopathyH LUNDBECK AS·Filed 2022·Application pending·0 cites
- 4584US12331123B2Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2022·Granted Jun 17, 2025·0 cites·22 claims
- 4684US2024084036A1Monoclonal antibodies against c-metGENMAB AS·Filed 2022·Application pending·0 cites
- 4783US2023374131A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2023·Application pending·0 cites
- 4882US10894833B2Agents, uses and methods for treatmentH LUNDBECK AS·Filed 2018·Granted Jan 19, 2021·2 cites·4 claims
- 4982US2025277040A1Agent, uses and methods for treatmentH LUNDBECK AS·Filed 2025·Application pending·0 cites
- 5080US11091553B2Monoclonal antibodies against HER2GENMAB AS·Filed 2017·Granted Aug 17, 2021·1 cites·20 claims
Showing the top 50 of 87 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Edward Norbert Van Den Brink files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →